Oracle finds itself caught in a rare and violent disconnect between its long-term growth narrative and the immediate pressures of its balance sheet. The stock has clawed back 4.95 percent to close at €111.60, a modest recovery from the multi-year low of €105.10 it touched on July 17. Yet that bounce, fueled by a bullish Mizuho analyst note and filings showing institutional buying, masks a deeper tension: the company’s credit markets are flashing warnings that its stock price alone cannot convey.
A 60 Percent Slide and a Contrarian Analyst Call
The numbers are stark. Oracle’s shares have cratered 60.49 percent from their September 2025 record high of €280.70, leaving the company with a market capitalization of roughly €318.97 billion. The stock sits just 5.52 percent above its 52-week trough, trading well below its 50-day and 200-day moving averages by approximately 26 percent and 31 percent respectively. The 14-day relative strength index had sunk to 33.5 before Tuesday’s uptick, signaling deeply oversold conditions.
Against this backdrop, Mizuho published a study arguing the sell-off has gone too far. The bank sees 164 percent upside from current levels, noting that Oracle trades at just 14 times expected non-GAAP earnings for 2027 — a steep discount to every comparable cloud infrastructure rival. The average analyst price target stands at €220.67, implying roughly 99 percent potential upside. That gap between where the stock trades and where analysts think it should be is itself a measure of the market’s current schizophrenia.
The $638 Billion Backlog That Can’t Fix Cash Flow
At the heart of the contradiction lies Oracle’s record-breaking order book. The company ended fiscal 2026 in June with remaining performance obligations of $638 billion, driven by surging demand for its Gen2 cloud infrastructure. That pipeline is the foundation of the bull case. But converting those commitments into recognized revenue requires enormous upfront spending — and that spending is crushing free cash flow.
Capital expenditures hit $55.7 billion in fiscal 2026, contributing to a negative free cash flow of $23.7 billion. Depreciation charges nearly doubled to $7.62 billion. To fund the buildout, Oracle took on $43 billion in new debt during the fiscal year and raised another $5 billion through equity. The company has signaled plans to raise an additional $40 billion through a combination of debt and share issuance, including a $20 billion stock offering already announced.
This capital-intensive expansion has triggered a credit downgrade. S&P Global recently cut Oracle’s rating from BBB to BBB-, citing the mounting debt burden tied to AI infrastructure. The five-year credit default swaps hit a record 203 basis points on Tuesday, a level that typically signals serious investor concern about repayment capacity.
Should investors sell immediately? Or is it worth buying Oracle?
Institutional Buyers Step In, But Questions Mount
Despite the credit anxiety, large investors are using the lower share price to build positions. A mandatory disclosure dated July 21 revealed that Commerzbank’s FI unit increased its Oracle stake by 6.4 percent in the first quarter, now holding 178,435 shares worth approximately $26.25 million at the time of filing. Overall, institutional ownership stands at 42.44 percent, suggesting that professional money managers are weighing the long-term AI opportunity against the short-term debt overhang.
The company is also taking steps to improve efficiency. Oracle has cut roughly 21,000 jobs — about 13 percent of its global workforce — as it integrates autonomous software and AI-driven automation into its data centers. Yet even these cost reductions are overshadowed by the scale of the capital demands ahead.
A Dividend That Defies the Balance Sheet
In a move that underscores management’s confidence — or perhaps its commitment to shareholder returns at any cost — Oracle is maintaining its quarterly dividend of $0.50 per share. The ex-dividend date passed on July 10, and the payout will go ahead even as the company digests tens of billions in new financing. The signal is clear: the payout program remains untouchable, regardless of the investment cycle’s strain on the balance sheet.
The Real Test Ahead
Oracle’s stock is now a proxy for a question that hangs over the entire AI infrastructure sector: Is the debt-fueled capacity buildout running ahead of the revenue conversion that is supposed to justify it? The company’s annualized 30-day volatility of 46.09 percent reflects the market’s struggle to price this tension.
The next quarterly update will be critical. Investors will be watching for signs that the $638 billion backlog is finally translating into recognized revenue, and whether free cash flow can begin to close the gap between Oracle’s growth promises and what its balance sheet can sustain. Until then, the stock remains trapped between a record order book and a credit market that is pricing in real risk — a split that makes Oracle one of the most contested names on Wall Street.
Ad
Oracle Stock: Buy or Sell?! New Oracle Analysis from July 22 delivers the answer:
The latest Oracle figures speak for themselves: Urgent action needed for Oracle investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from July 22.
Oracle: Buy or sell? Read more here...
